Evidence map›Paper›PMID 42429947›Full record

ArticleCancer immunology, immunotherapy : CII2026

Association between cumulative lifetime exposure to reproductive hormones and tumor-infiltrating lymphocytes, CD4 +, and CD8 + T cells among women with breast cancer.

Yidan Zhang, Rand T Akasheh, Angela R Omilian, Bo Qin, Nur Zeinomar, Song Yao, Chi-Chen Hong, Elisa V Bandera, Christine B Ambrosone, Thaer Khoury and 1 more

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yidan Zhang *Division of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University, 3650 Olentangy River Rd., Columbus, OH, 43214, USA.
Rand T Akasheh *Division of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University, 3650 Olentangy River Rd., Columbus, OH, 43214, USA.
Angela R OmilianDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Bo QinCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Nur ZeinomarCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Chi-Chen HongDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Thaer KhouryDepartment of Pathology & Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Ting-Yuan David ChengDivision of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University, 3650 Olentangy River Rd., Columbus, OH, 43214, USA. ting-yuan.cheng@osumc.edu.ORCID https://orcid.org/0000-0002-4105-828X

Funding

Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European AncestryR01CA247281 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., AMBROSONE, CHRISTINE B. · 2020 to 2024
$5.2M
American Cancer Society RSG-23-1143513-01-CTPSNCI NIH HHS R01 CA247281
6 · The paper itself

Abstract

backgroundReproductive hormones may influence immune responses to tumors. Tumor-infiltrating lymphocytes (TILs), CD4 +, and CD8 + T cell densities are markers of immune activity and breast cancer prognosis. We examined associations between lifetime reproductive hormone exposure, tumor immune infiltration, and survival among women with breast cancer.

methodsThe study included invasive breast cancer cases in the Women's Circle of Health Study and the Women's Circle of Health Follow-up Study. Lifetime endogenous hormone exposure (LHEendo) was defined as reproductive years plus pregnancy duration minus breastfeeding duration; lifetime exogenous hormone exposure (LHEexo) was defined as the combined cumulative duration of oral contraceptive and hormone replacement therapy use. TILs were scored as ordered percentage values from 0 to 100% stromal area; CD4 + /CD8 + T cell densities were quantified by immunohistochemistry. TILs were modeled using ordinal logistic regression, and CD4 + /CD8 + T cell densities were modeled using gamma generalized linear models among participants with positive density values, with covariates selected by directed acyclic graphs. Overall survival was assessed using Cox proportional hazards models, and breast cancer-specific survival was assessed using Fine-Gray competing-risk models.

resultsAmong 1195 women with valid TILs measurements, 553 and 610 had CD4 + and CD8 + T cell density data, respectively. Across all tumor molecular subtypes, a 1-year increment of LHEendo was associated with a 2.85% decrease in CD8 + T cell density (95% CI - 5.14%, - 0.61%). LHEendo was associated with lower odds of being in a higher TIL level among women with hormone receptor (HR) + /HER2- tumors (OR = 0.977, 95% CI 0.957, 0.997), although the interaction by molecular subtype was not statistically significant. LHEexo was associated with lower risk of all-cause mortality (HR = 0.979, 95% CI 0.960, 0.998). TIL-stratified analyses suggested that this association may be more apparent among women with TILs ≥ 50% (HR = 0.90, 95% CI = 0.82, 0.99; P-interaction = 0.10).

conclusionsLifetime endogenous hormone exposure was associated with lower CD8 + T cell density overall, with exploratory findings of lower TIL levels among women with HR + /HER2- tumors. Lifetime exogenous hormone exposure was associated with a lower risk of all-cause mortality, with possible variation by TIL levels.

Indexed as

Breast NeoplasmsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingAdultFemaleFollow-Up StudiesHumansMiddle AgedPrognosisBreast cancerCD4-positive T-lymphocytesCD8-positive T-lymphocytesHormone useReproductive historyTumor-infiltrating lymphocyte

Identifiers

PMID42429947
PMCPMC13638916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.